论文部分内容阅读
目的探究解聚素-金属蛋白酶17(ADAM17)、表皮生长因子受体(EGFR)、Ki-67在脑胶质瘤中的表达及临床预后评估。方法 64例脑胶质瘤蜡块组织,其中24例低度恶性胶质瘤组织为A组,40例高度恶性胶质瘤组织为B组,同期20例正常脑组织为对照组,通过免疫组化法检测ADAM17、EGFR、Ki-67在3组组织中阳性率,并分析其相关性。结果 64例脑胶质瘤蜡块组织ADAM17、EGFR、Ki-67总阳性率均高于对照组(P<0.05);A组ADAM17、EGFR、Ki-67阳性率低于B组(P<0.05);EGFR与ADAM17呈正相关(r=0.611,P<0.05);Ki-67与ADAM17呈正相关(r=0.573,P<0.05);EGFR与Ki-67呈正相关(r=0.445,P<0.05)。结论 ADAM17、EGFR、Ki-67在脑胶质瘤中阳性率较高,且与脑胶质瘤恶性程度具有相关性,可为临床诊疗及预后提供指导。
Objective To investigate the expression of ADAM17, epidermal growth factor receptor (EGFR) and Ki-67 in glioma and the clinical prognosis. Methods Sixty-four patients with glioma were divided into two groups: group A (24 cases), group B (Group B), group B (40 cases), normal group (20 cases) as control group The positive rates of ADAM17, EGFR and Ki-67 in 3 groups of tissues were detected and their correlations were analyzed. Results The positive rates of ADAM17, EGFR and Ki-67 in 64 cases of glioma were higher than those in control group (P <0.05). The positive rates of ADAM17, EGFR and Ki-67 in group A were lower than those in group B (R = 0.611, P <0.05). There was a positive correlation between Ki-67 and ADAM17 (r = 0.573, P <0.05) . Conclusion The positive rate of ADAM17, EGFR and Ki-67 in gliomas is high, which is correlated with the malignant degree of glioma, which may provide guidance for the clinical diagnosis and prognosis.